Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry.

摘要: Background. Cannabidiol (CBD) is a major chemical compound present in Cannabis sativa. CBD nonpsychotomimetic substance, and it considered one of the most promising candidates for treatment psychiatric disorders. Objective. The aim this review to illustrate state art about scientific research evidence effectiveness patients. Methods. This collects main findings on potential role field, results clinical trials carried out patients are commented. A was conducted PUBMED, SCOPUS, ScienceDirect databases using combinations words cannabidiol, psychiatry, neuropsychiatric. Results. Preclinical studies psychiatry were collected further discussed. We found four describing effects patients: two schizophrenic other affected by generalized social anxiety disorder (SAD). Conclusion. Results from these suggest that may have development new therapeutic strategies mental diseases, they justify an in-depth commitment field. However, we show instead still poor limited schizophrenia anxiety, needs be implemented with